SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · IEX Real-Time Price · USD
1.110
+0.030 (2.78%)
Jul 19, 2024, 4:00 PM EDT - Market closed
SLS Employees
SELLAS Life Sciences Group had 16 employees as of December 31, 2023. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
n/a
Profits / Employee
-$2,238,063
Market Cap
64.11M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Prenetics Global | 324 |
HOOKIPA Pharma | 179 |
Vor Biopharma | 168 |
Allakos | 131 |
ProPhase Labs | 113 |
Entera Bio | 18 |
Milestone Scientific | 17 |
Aileron Therapeutics | 15 |
SLS News
- 6 days ago - SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia - GlobeNewsWire
- 14 days ago - SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia - GlobeNewsWire
- 4 weeks ago - SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia - GlobeNewsWire
- 5 weeks ago - SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia - GlobeNewsWire
- 6 weeks ago - SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML - GlobeNewsWire
- 2 months ago - SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level - GlobeNewsWire
- 3 months ago - SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study - GlobeNewsWire